IN8bio, Inc.
IN8bio, Inc. (INAB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · INAB · as of Jun 9, 2026
Key Statistics
Explore IN8bio, Inc. Data
inab stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 75.0%
The INAB analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $4.00, representing +177.78% upside from the current price of $1.44.
Competitors & Peers
inab competitorsINAB
ACXP
APRE
APVO
BCDA
GLTOStock Performance
Full HistoryAbout IN8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various for…
what is in8bio, inc. · inab stock overview · in8bio, inc. company profile · who is in8bio, inc. ceo · inab NASDAQ · in8bio, inc. headquarters · in8bio, inc. business segments
About Stock Overview & Key Data
IN8bio, Inc. (INAB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 30, 2021. As of the latest trading session, INAB stock price is $1.44, with a market capitalization of $6.7M. The stock has returned -53.25% over the past 12 months and -38.46% year-to-date.
According to 4 Wall Street analysts, the consensus rating for IN8bio, Inc. stock is Buy, with an average 12-month price target of $4.00. In fiscal year 2025, IN8bio, Inc. reported revenue of — and net income of -$19.4M. For detailed data — including IN8bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, IN8bio, Inc. (INAB) stock price is $1.44. The stock is traded on NASDAQ under the ticker symbol INAB. The 52-week range is $1.17 – $3.66.